Author Information An event is serious (FDA MedWatch definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * requires intervention to prevent permanent impairment or damage Two girls developed drug-induced liver injury while receiving ...
I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time. Report Problems to the Food and Drug Administration You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website...
Eurofarma offers wide range of pharmaceutical products which includes cyclobenzaprine hydrochloride. It belongs to prescription drugs category. Therapeutical class: centrally acting muscle relaxant. Active ingredient: cyclobenzaprine hydrochloride. Packaging: 15 pills of 5 mg, 30 pills of 5 mg, 15 pills ...
Ann Intern Med 2002; 137: 704. Effects on the liver. Raised liver enzyme values have occurred rarely in patients receiving losartan. Severe, acute hepatotoxicity developed in a patient 1 month after losartan was substituted for enalapril because of ACE inhibitor-induced cough.1 The patient ...
Losartan belongs to the class of angiotensin II receptor blockers, which has significant renal benefits in patients with type 2 diabetes and nephropathy and is generally well tolerated [62,63]. The drug has a long half-life and is characterized by stability and high efficacy; At the same time...
“FDA previously estimated that if 8,000 people took the highest valsartan dose (320 mg) containing NDMA from the recalled batches daily for four years, there may be one additional case of cancer over the lifetimes of the 8,000 people. That estimate was based on the highest daily dose, ho...
Interruption of the renin-angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available fo... BM Brenner,ME Cooper,DD Zeeuw,... - 《N Engl J Med》 被引量: 1.5万发表: 2001年 Cardiovascular morbidity and mortality in the ...
E-mail: rakugi@geriat.med.osaka-u.ac.jp Received 28 February 2014; revised 30 April 2014; accepted 3 May 2014; published online 3 July 2014 Losartan/HTZ vs. losartan in Japanese subjects H Rakugi et al 1043 A fixed-dose combination of losartan potassium 50 mg (L50), an angiotensin ...
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study Am J Med, 113 (2002), pp. 359-364 View PDFView articleView in ScopusGoogle Scholar 2 H. Vidaillet, J.F. Granada, P.H. Chyou, et al. A population-ba...
Ojha U, Ruddaraju S, Sabapathy N et al (2022) Current and emerging classes of pharmacological agents for the management of hypertension. Am J Cardiovasc Drugs 22:271–285 Article PubMed Google Scholar Shah PA, Sharma P, Shah JV et al (2015) Simultaneous analysis of losartan, its active...